Discordance of meropenem versus imipenem activity against Acinetobacter baumannii

International Journal of Antimicrobial Agents

Volumn 28, Issue 4, 2006, Pages 376-377

  Ikonomidis, Alexandros ^a   Pournaras, Spyros ^a   Maniatis, Antonios N ^a   Legakis, Nicholas J ^b   Tsakris, Athanassios ^b  

^a UNIVERSITY OF THESSALY   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; IMIPENEM; MEROPENEM;

ACINETOBACTER BAUMANNII; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONSENSUS; DRUG ACTIVITY; GENOTYPE; HUMAN; LETTER; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR CLONING; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; HUMANS; IMIPENEM; THIENAMYCINS;

EID: 33748898882     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.07.007     Document Type: Letter

References (10)

1. Wroblewska M.M., Rudnicka J., Marchel H., and Luczak M. Multidrug-resistant bacteria isolated from patients hospitalised in Intensive Care Units. Int J Antimicrob Agents 27 (2006) 285-289
2. Pournaras S., Markogiannakis A., Ikonomidis A., et al. Outbreak of multiple clones of imipenem-resistant Acinetobacter baumannii isolates expressing OXA-58 carbapenemase in an intensive care unit. J Antimicrob Chemother 57 (2006) 557-561
3. Coelho J., Woodford N., Turton J., and Livermore D.M. Multiresistant acinetobacter in the UK: how big a threat?. J Hosp Infect 58 (2004) 167-169
4. Jones R.N., Sader H.S., Fritsche T.R., and Rhomberg P.R. Carbapenem susceptibility discords among Acinetobacter isolates. Clin Infect Dis 42 (2006) 158
5. Rhomberg P.R., and Jones R.N. Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: report from the MYSTIC Program (2002) in North America. Diagn Microbiol Infect Dis 47 (2003) 365-372
6. Garcia-Rodriguez J.A., and Jones R.N. Antimicrobial resistance in gram-negative isolates from European intensive care units: data from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme. J Chemother 14 (2002) 25-32
7. Jones R.N., Sader H.S., and Beach M.L. Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997-2001). Int J Antimicrob Agents 22 (2003) 551-556
8. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 15th informational supplement. M100-S15. Wayne, PA: CLSI; 2005.
9. Poirel L., Marque S., Heritier C., Segonds C., Chabanon G., and Nordmann P. OXA-58, a novel class D β-lactamase involved in resistance to carbapenems in Acinetobacter baumannii. Antimicrob Agents Chemother 49 (2005) 202-208
10. Franceschini N., Caravelli B., Docquier J.-D., et al. Purification and biochemical characterization of the VIM-1 metallo-β-lactamase. Antimicrob Agents Chemother 44 (2000) 3003-3007